Top

Published in:

01-03-2007 | Original Article

Whole blood laboratory model of thrombocytopenia for use in evaluation of hemostatic interventions

Authors: Ole Halfdan Larsen, Jørgen Ingerslev, Benny Sørensen

Published in: Annals of Hematology | Issue 3/2007

Abstract

This study describes a laboratory model of whole blood (WB) thrombocytopenia established with blood from healthy volunteers. We obtained a mean platelet count of 16 × 10⁹/l (95% confidence interval, 10–22) in WB by repeatedly replacing the platelet-rich supernatant with autologous platelet-poor plasma from the same individual. Thrombelastographic profiles of WB clot formation and WB clot stability were performed in parallel with measurements of WB platelet aggregation response. Thrombocytopenia reduced the maximum rate of WB clot formation, while ex vivo addition of platelets reversed the coagulopathy of thrombocytopenia. Control experiments revealed minimal changes in coagulation factors, distribution of bloods cells, and platelet activation capabilities. The WB model appears useful in research, development, and evaluation of the effects of hemostatic interventions in thrombocytopenia.

George JN (2000) Platelets. Lancet 355:1531–1539PubMedCrossRef

Blajchman MA (2003) Substitutes and alternatives to platelet transfusions in thrombocytopenic patients. J Thromb Haemost 1:1637–1641PubMedCrossRef

Blajchman MA, Lee DH (1997) The thrombocytopenic rabbit bleeding time model to evaluate the in vivo hemostatic efficacy of platelets and platelet substitutes. Transfus Med Rev 11:95–105PubMedCrossRef

Tranholm M, Rojkjaer R, Pyke C, Kristensen AT, Klitgaard B, Lollike K et al (2003) Recombinant factor VIIa reduces bleeding in severely thrombocytopenic rabbits. Thromb Res 109:217–223PubMedCrossRef

Kjalke M, Ezban M, Monroe DM, Hoffman M, Roberts HR, Hedner U (2001) High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. Br J Haematol 114:114–120PubMedCrossRef

Gerotziafas GT, Chakroun T, Depasse F, Arzoglou P, Samama MM, Elalamy I (2004) The role of platelets and recombinant factor VIIa on thrombin generation, platelet activation and clot formation. Thromb Haemost 91:977–985PubMed

Oshita K, Az-ma T, Osawa Y, Yuge O (1999) Quantitative measurement of thromboelastography as a function of platelet count. Anesth Analg 89:296–299PubMedCrossRef

Katori N, Tanaka KA, Szlam F, Levy JH (2005) The effects of platelet count on clot retraction and tissue plasminogen activator-induced fibrinolysis on thrombelastography. Anesth Analg 100:1781–1785PubMedCrossRef

Peyrou V, Lormeau JC, Herault JP, Gaich C, Pfliegger AM, Herbert JM (1999) Contribution of erythrocytes to thrombin generation in whole blood. Thromb Haemost 81:400–406PubMed

10.

Butenas S, Branda RF, van’t Veer C, Cawthern KM, Mann KG (2001) Platelets and phospholipids in tissue factor-initiated thrombin generation. Thromb Haemost 86:660–667PubMed

11.

McEver RP (2001) Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost 86:746–756PubMed

12.

Moir E, Robbie LA, Bennett B, Booth NA (2002) Polymorphonuclear leucocytes have two opposing roles in fibrinolysis. Thromb Haemost 87:1006–1010PubMed

13.

Sørensen B, Johansen P, Christiansen K, Woelke M, Ingerslev J (2003) Whole blood coagulation thrombelastographic profiles employing minimal tissue factor activation. J Thromb Haemost 1:551–558PubMedCrossRef

14.

Sørensen B, Ingerslev J (2004) Whole blood clot formation phenotypes in hemophilia A and rare coagulation disorders. Patterns of response to recombinant factor VIIa. J Thromb Haemost 2:102–110PubMedCrossRef

15.

Sørensen B, Ingerslev J (2006) A direct thrombin inhibitor studied by dynamic whole blood clot formation. Haemostatic response to ex-vivo addition of recombinant factor VIIa or activated prothrombin complex concentrate. Thromb Haemost 96:446–453PubMed

16.

Hvitfeldt Poulsen L, Christiansen K, Sørensen B, Ingerslev J (2006) Whole blood thrombelastographic coagulation profiles using minimal tissue factor activation can display hypercoagulation in thrombosis-prone patients. Scand J Clin Lab Invest 66:329–336PubMedCrossRef

17.

Johansen RF, Sørensen B, Ingerslev J (2006) Acquired haemophilia: dynamic whole blood coagulation utilized to guide haemostatic therapy. Haemophilia 12:190–197PubMedCrossRef

18.

Fenger-Eriksen C, Anker-Moller E, Heslop J, Ingerslev J, Sørensen B (2005) Thrombelastographic whole blood clot formation after ex vivo addition of plasma substitutes: improvements of the induced coagulopathy with fibrinogen concentrate. Br J Anaesth 94:324–329PubMedCrossRef

19.

Sørensen B, Ingerslev J (2005) Tailoring haemostatic treatment to patient requirements—an update on monitoring haemostatic response using thrombelastography. Haemophilia 11(Suppl 1):1–6PubMedCrossRef

20.

Rivard GE, Brummel-Ziedins KE, Mann KG, Fan L, Hofer A, Cohen E (2005) Evaluation of the profile of thrombin generation during the process of whole blood clotting as assessed by thrombelastography. J Thromb Haemost 3:2039–2043PubMedCrossRef

21.

Rinder HM, Ault KA (1998) Platelet activation and its detection during the preparation of platelets for transfusion. Transfus Med Rev 12:271–287PubMedCrossRef

22.

Kostelijk EH, Fijnheer R, Nieuwenhuis HK, Gouwerok CW, de KD (1996) Soluble P-selectin as parameter for platelet activation during storage. Thromb Haemost 76:1086–1089PubMed

Title: Whole blood laboratory model of thrombocytopenia for use in evaluation of hemostatic interventions
Authors: Ole Halfdan Larsen
Jørgen Ingerslev
Benny Sørensen
Publication date: 01-03-2007
Publisher: Springer-Verlag
Published in: Annals of Hematology / Issue 3/2007
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-006-0223-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2007

Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology

Intensive blood transfusion support in acquired hemophilia A

Severe infectious complications in a patient treated with rituximab for idiopathic thrombocytopenic purpura

Downregulation of cyclooxygenase-2 expression and activation of caspase-3 are involved in peroxisome proliferator-activated receptor-γ agonists induced apoptosis in human monocyte leukemia cells in vitro

Thrombotic thrombocytopenic purpura as the initial presentation of Pneumocystis jiroveci pneumonia in an immunocompetent patient

Limited effect of rituximab on thrombocytopaenia and anticardiolipin antibodies in a patient with primary antiphospholipid syndrome

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials